Advertise on podcast: EP Edge Journal Watch

Pulsed field ablation (PFA) has rapidly reshaped atrial fibrillation ablation, but true clinical validation depends on durable one-year outcomes, not early feasibility or acute safety alone. In this EP Edge Journal Watch Special Edition, Dr. Niraj Sharma delivers a comprehensive, system-level analysis of the Abbott VOLT IDE one-year data, now completing the 12-month efficacy and safety landscape across major U.S. PFA platforms. This episode critically reviews and contextualizes results from the VOLT IDE trial alongside other pivotal and near-pivotal studies, including ADVENT, ADVANTAGE-AF, AdmIRE, SPHERE-9 first-in-human, and SPHERE-Per-AF. The discussion spans paroxysmal, persistent, and advanced AF populations, with attention to how ablation strategy (PVI-only vs adjunctive lesions), patient risk profile, and post-ablation monitoring intensity influence reported outcomes. Key themes include one-year efficacy versus composite effectiveness, freedom from atrial arrhythmias, repeat procedures, and major safety endpoints such as stroke, tamponade, and esophageal injury. Rather than ranking technologies, this episode emphasizes methodology, trial design, and clinical context, explaining why efficacy signals differ across studies and how these data should be interpreted in everyday electrophysiology practice. For additional references, detailed tables, graphics, and deeper comparative analysis, visit the LinkedIn EP Edge newsletter and Substack at ephedge.substack.com. If you have suggestions or concerns, you can reach Dr. Sharma at [email protected]

In EP Edge Journal Watch – Issue 9 (February 2026), we take a comprehensive, clinically grounded look at the evolving management of ventricular tachycardia (VT)—from last-line noninvasive therapies to next-generation devices, pharmacologic strategy, and infection prevention. This episode critically reviews the STRA-MI-VT trial, examining stereotactic arrhythmia radioablation (STAR) for refractory VT with a unique focus on coronary safety using serial coronary CT angiography. We explore why early VT suppression occurs after radioablation and what emerging mechanistic data suggest about electrophysiologic remodeling beyond fibrosis. We then turn to contemporary VT decision-making with a deep dive into the VANISH2 substudy, comparing first-line catheter ablation with antiarrhythmic drug therapy, highlighting where ablation clearly outperforms sotalol and rivals amiodarone—without long-term extracardiac toxicity. Next, we examine modular defibrillation systems combining subcutaneous ICDs with leadless antitachycardia pacing, unpacking ATP effectiveness, complication rates, and the critical nuance behind so-called “inappropriate” therapies. We also review the latest data on dual-chamber leadless pacing, demonstrating high real-world AV synchrony and outlining what questions remain unanswered. The episode concludes with two essential but often under-discussed domains: Why antiarrhythmic drugs still matter in 2026, using updated EHRA frameworks for safer, more rational useWhat the CHLOVIS trial teaches us about CIED infection prevention—and why skin antisepsis alone is not the decisive factorAs always, EP Edge Journal Watch prioritizes clinical context, trial design, limitations, and practical implications, helping electrophysiologists cut through signal versus noise.  Looking for More Detail? For expanded references, trial tables, figures, and visual summaries, visit the EP Edge Journal Watch LinkedIn Newsletter. Each study discussed in this episode is accompanied there by: Trial-at-a-glance summariesKey graphs and imaging highlightsStructured critical appraisalClinical interpretation beyond the abstractIf you prefer to read, review figures, or reference the data later, the LinkedIn newsletter is the ideal companion to this podcast episode. If you have questions, feedback, or clinical thoughts, feel free to reach out directly at [email protected]

In EP Edge Journal Watch – Issue 8 (2026), we deliver a comprehensive, evidence-driven analysis of the most important and practice-shaping studies in contemporary cardiac electrophysiology. This episode begins with ventricular tachycardia storm, examining why in-hospital mortality remains high despite aggressive rhythm control. We break down the CHAMPS score, focusing on patient selection, systemic illness, statistical modeling, and what the data truly reveal about ablation timing, competing risks, and survival. We then turn to implantable cardioverter-defibrillators, exploring long-term outcomes and real-world trade-offs between subcutaneous and transvenous ICD systems. A detailed discussion of inappropriate shock mechanisms highlights the balance between lead durability, sensing biology, atrial arrhythmias, oversensing, and device programming strategies that matter over years—not months. The episode moves into atrial fibrillation beyond pulmonary vein isolation. We analyze adjunctive renal denervation during AF ablation, reviewing trial methodology, statistical power, and why biologic plausibility does not always translate into clinical significance. We also examine atrial fibrillation outcomes in patients with obstructive sleep apnea, addressing large observational datasets, propensity matching, effect sizes, and the critical distinction between association and causation. Practical electrophysiology extends into the emergency department as well. This episode reviews data on preventing diltiazem-induced hypotension in atrial fibrillation with rapid ventricular response, focusing on physiologic rationale, dosing considerations, and where this strategy fits into real-world care. Finally, we close with a true paradigm shift in arrhythmia management: patient-delivered therapy for paroxysmal supraventricular tachycardia. We explore how intranasal therapy allows selected patients to terminate SVT outside the hospital, what the trial data support, and how this may reshape care pathways, patient autonomy, and healthcare utilization. Throughout the episode, EP Edge Journal Watch emphasizes study design, statistical interpretation, limitations, and clinical applicability, cutting through hype to deliver insights that matter for practicing electrophysiologists, cardiologists, and advanced trainees. This episode is essential listening for anyone interested in ventricular arrhythmias, ICD therapy, atrial fibrillation ablation, device strategy, emergency rhythm management, and the future of patient-centered electrophysiology care.

EP-EDGE Journal Watch – Issue 7 (January 2026) Advanced Cardiac Electrophysiology Podcast | AF, DOACs, PFA, Devices & Heart Failure In EP-EDGE Journal Watch Issue 7, Dr. Niraj Sharma delivers a high-impact, clinician-focused breakdown of the most practice-changing cardiac electrophysiology studies published in late 2025 and early 2026. This episode moves beyond headlines to translate data into actionable decisions for the EP lab and clinic. Key topics covered in this episode include: • DOAC adherence and stroke risk in atrial fibrillation How many anticoagulant doses can patients truly miss before stroke risk rises sharply? A landmark real-world analysis using machine-learning–optimized adherence modeling challenges the long-standing 80% adherence rule and shows why near-perfect DOAC consistency is required for stroke prevention. • Stressor-associated atrial fibrillation Once considered “reversible,” AF occurring during surgery, sepsis, or myocardial infarction is now shown to carry high recurrence, stroke, heart failure, and mortality risk. This episode explains why reassurance alone is no longer appropriate—and how long-term management should change. • Pulsed-field ablation (PFA) and laryngospasm A newly recognized, high-acuity airway complication associated with PFA under general anesthesia. Learn the proposed mechanisms, anesthesia implications, and how EP labs should adapt airway and neuromuscular blockade strategies. • Nanosecond PFA versus radiofrequency ablation for paroxysmal AF A randomized trial and editorial analysis comparing efficacy, procedural efficiency, fluoroscopy exposure, and safety—shifting the discussion from rhythm success to workflow and radiation trade-offs. • PFAS regulations and electrophysiology devices Why conflating harmful PFAS with inert fluoropolymers threatens EP device supply chains—and why electrophysiologists must engage in science-based policy advocacy. • PVC location and incident heart failure Large community-based data reveal that where PVCs originate matters more than how many occur, with LV and epicardial PVCs carrying disproportionate HF risk. • 2025 EHRA consensus on CIED upgrades and downgrades A critical, EP-focused analysis of device lifecycle management, including venous access strategies, infection prevention, conduction system pacing, lead extraction, and when not to wait for battery depletion. Why listen? This episode is designed for electrophysiologists, cardiologists, fellows, advanced practice providers, and EP lab professionals seeking concise, evidence-based insights with immediate clinical relevance. EP-EDGE Journal Watch delivers weekly EP intelligence. Subscribe:  https://lnkd.in/e-Wa4diC EP-EDGE (main newsletter) provides deep-dive monthly analyses on major electrophysiology themes. Subscribe: https://lnkd.in/ep3NdZUz Subscribe, listen, and stay ahead of the curve in cardiac electrophysiology.

EP Edge Journal Watch Podcast — Issue 6 (January 2026) Left Atrial Appendage Occlusion, AF Ablation Insights, Post-TAVR Conduction, ICU Anticoagulation & Translational EP Signals EP Edge Journal Watch is your high-yield, evidence-driven electrophysiology podcast—designed for busy clinicians who want clinical relevance, mechanistic insight, and practice-changing nuance without wading through every paper. In Issue 6 (January 2026), we anchor the episode around Left Atrial Appendage Occlusion (LAAO)—examining long-term randomized outcomes, implant mechanics that truly matter, and frontier strategies for the most complex patients—then expand into essential EP topics you’ll actually use on rounds. What’s covered in this episode? 1.      LAAO vs Oral Anticoagulation — Long-Term Outcomes We break down a contemporary randomized trial meta-analysis (including OPTION) examining: Stroke and systemic embolismHemorrhagic vs non-procedural bleedingA provocative mortality signal favoring LAAO Practical implications for counseling ablation patients and high-bleeding-risk populations.2.      WATCHMAN FLX Mechanics — Why Compression Matters A deep dive into device sizing and compression: Over-compression thresholdsImpact on peridevice leak (PDL)How this data should influence real-world implant decisions.3.      Persistent LAA Thrombus — Is There a Salvage Path? We discuss a multicenter experience using: Percutaneous aspiration thrombectomyEmbolic protection strategiesSame-session, no-touch LAA closure A feasibility signal—not for routine practice, but critical for expert centers facing clinical dead-ends.OPTION Sub-Analysis — Does LAAO Worsen AF Recurrence? Using the largest randomized dataset available: Concomitant vs staged LAAO with ablationAF recurrence, cardioversion, redo ablationWhy “no AF recurrence” ≠ “no stroke risk”.4.      Post-TAVR Conduction Disturbances A physiology-forward look at: Intraprocedural vs delayed high-grade AV blockHV interval and PR prolongation as rule-out toolsPractical EP risk stratification after TAVR.5.      Early Recurrence After Persistent AF Ablation Insights from CAPLA challenge the traditional blanking period: Timing and burden of early recurrenceWhy late blanking-period events matter mostHow this should reshape post-ablation follow-up.6.      Septic Shock + AF — ICU Anticoagulation Reality A clinically uncomfortable but crucial topic: Therapeutic anticoagulation in septic shockMortality vs bleeding tradeoffsWhy EP input matters even in the ICU.7.      Sex Hormones & Torsades de Pointes — A Translational EP Signal A paradigm-shifting study linking: Hypogonadism, hyperestrogenism, and QT prolongationCellular electrophysiology and real-world TdP severityA new biologic layer in arrhythmic risk.   Want more? Subscribe to: EP Edge Journal Watch (Weekly): https://lnkd.in/e-Wa4diC A concise, high-yield weekly digest of the most important EP studies—curated, contextualized, and clinically translated so you don’t have to read everything to understand what matters. The EP Edge Newsletter (In-Depth Issues): https://lnkd.in/ep3NdZUz Our flagship, deep-dive editions, where we go far beyond abstracts—breaking down: Technology and mechanismsTrial design and statistical nuanceEfficacy, durability, and complicationsWhat truly differentiates one approach from anotherThe upcoming EP Edge deep-dive issue on Pulsed Field Ablation will do exactly that—offering a comprehensive, evidence-driven analysis of PFA platforms, mechanisms, outcomes, safety, and where the field is headed next.

EP Edge Journal Watch — January 2026 | Issue #5 Pulsed Field Ablation, Device Therapy, and the Era of Personalized EP Welcome to EP Edge Journal Watch – Issue #5 (January 2026), your high-yield, evidence-driven electrophysiology podcast designed for practicing EPs who want more than just abstracts. As 2026 begins, electrophysiology is entering a defining phase—where pulsed field ablation (PFA) matures beyond feasibility, device therapy is reframed by competing risk, and “one-size-fits-all” ablation strategies give way to personalization. In this episode, Dr. Niraj Sharma MD FACC FHRS breaks down practice-changing trials, real-world registries, and mechanistic insights that are actively reshaping how we approach atrial fibrillation ablation, ICD decision-making, leadless pacing, and AF progression. What’s covered in this issue: Long-term ICD outcomes in nonischemic cardiomyopathy Why preventing sudden death does not always translate into survival benefit—and how age and competing risk matter.Leadless pacing evolution Dual-chamber leadless pacemakers, operator learning curves, and why high acute atrial thresholds don’t predict chronic failure.Reducing CIED infections How a simple iodinated adhesive drape significantly lowers contamination and infection risk.AF progression as a biologic signal Why device-detected AF progression predicts mortality, heart failure, and stroke risk.Monitoring-driven AF management How implantable cardiac monitors change rhythm-control strategies and outcomes.Pulsed Field Ablation at scale CE-Mark data, IDE trials, and the MANIFEST-US registry defining safety, durability, and workflow in real-world PFA.Rare but serious delayed PFA complications What every electrophysiologist should know about delayed ischemia and malignant arrhythmias.Personalized AF ablation strategies LA wall thickness–guided ablation, sex-specific outcomes, and patient-factor–driven lesion optimization beyond PVI-only.Why this episode matters: This is not headline medicine. This is mechanism-aware, data-literate electrophysiology, focused on: Durability over acute successPrecision over dogmaBiology over empiricismWhether you’re performing AF ablation weekly, implanting devices, or shaping EP programs, this episode provides context you can apply immediately in the lab and clinic. Want more? EP Edge Journal Watch (Weekly): concise, curated EP research updatesEP Edge Newsletter (In-Depth): deep dives into trials, mechanisms, and clinical implicationsAll references, figures, and infographics discussed in this episode are available in the EP Edge Journal Watch LinkedIn Newsletter. Subscribe, follow, and stay at the edge of electrophysiology. — Niraj Sharma, MD FACC FHRS Cardiac Electrophysiologist | Founder, EP Edge

In this December 2025 episode of EP Edge Journal Watch, Dr. Niraj Sharma breaks down the most provocative atrial fibrillation trials of the year—studies that force us to rethink what really drives AF outcomes beyond the ablation lesion  EP EDGE JW Dec 2025 Newsletter. We dive deep into four game-changing themes shaping modern electrophysiology: Can we safely stop anticoagulation after AF ablation?A critical analysis of OCEAN (NEJM 2025) and ALONE-AF, exploring DOAC de-escalation, aspirin as a comparator, and whether selected AF-free patients may safely discontinue oral anticoagulation.  Is AF ablation real—or partly placebo?A deep dive into sham-controlled ablation trials, including SHAM-PVI and the landmark PFA-SHAM trial, providing definitive evidence that both thermal and pulsed-field ablation deliver true reductions in AF burden and meaningful quality-of-life benefits.  Are metabolic drugs the next AF substrate therapy?We examine emerging data on GLP-1 receptor agonists (semaglutide), metformin, and SGLT2 inhibitors after AF ablation—highlighting which therapies reduce recurrence and which fail when used purely as off-label antiarrhythmics.  Why do women run faster sinus rates than men?A fascinating look at human sinoatrial node transcriptomics, explaining sex-specific heart-rate biology and its implications for inappropriate sinus tachycardia, sinus node dysfunction, and AF progression. What you’ll learn Why the “DOAC for life” paradigm after AF ablation is beginning to crackHow sham trials finally settle the debate about ablation’s true efficacyWhich metabolic drugs actually modify AF substrate—and which do notHow sex-specific sinus node biology should influence EP decision-makingThis episode moves electrophysiology beyond lesion sets toward precision, whole-patient AF care—integrating stroke prevention, substrate modification, and biologic reality. Full trial graphics, references, and detailed breakdowns are available in the EP Edge Journal Watch – December 2025 Issue on LinkedIn. Questions or feedback? Email [email protected] This is EP Edge Journal Watch — where data meets clinical judgment.

Smartwatches are now among the most widely used heart-monitoring tools in the world — but how accurate are they really at detecting AFib? In this December 2025 Issue 3 of EP-Edge Journal Watch, Dr. Niraj Sharma, cardiologist and cardiac electrophysiologist, breaks down the strongest evidence to date on smartwatch AFib detection, Apple Watch ECG performance, false alerts, AF burden tracking, and post-ablation monitoring. With more than 450 million global smartwatch users and growing, both clinicians and patients rely on devices like the Apple Watch, Fitbit, Samsung Galaxy Watch, and Withings for early arrhythmia detection. This episode answers the questions everyone is asking: What You’ll Learn in This Episode • How accurate are smartwatches for detecting atrial fibrillation (AFib)? A breakdown of major meta-analyses across Apple Watch ECG, PPG sensors, and multi-device comparisons — including real numbers on sensitivity, specificity, and real-world diagnostic performance. • Why do so many smartwatch alerts end up being false positives? Dr. Sharma explains the positive predictive value problem in low-prevalence populations and why young, healthy users often receive incorrect AFib notifications. • Apple Watch ECG vs. Holter monitor vs. implantable monitor Find out when a smartwatch is good enough, when a clinical monitor is necessary, and when an implantable cardiac monitor (ICM) remains the gold standard. • Can smartwatches reliably detect AFib recurrence after ablation? Review of the CIRCADOSE data showing smartwatch AFib-burden algorithms compared with implantable monitors — and when they outperform intermittent Holters. • Why EP patients get so many inconclusive smartwatch readings Including pacing, left bundle branch block, low-voltage signals, and ectopy — and when to move directly to patch or implantable monitoring. Clinical Framework & Real-World Decision Pathways Dr. Sharma provides practical, evidence-backed direction for: Confirming AFib from smartwatch ECG stripsManaging stroke risk using the CHADS-VASc (spoken as “Chads Two Vask”) scorePost-ablation AFib surveillanceChoosing between smartwatch monitoring, Holter monitoring, and ICMCounseling anxious, low-risk patients on false AFib alertsSupporting shared decision-making with objective dataWho This Episode Is For Cardiac electrophysiologistsCardiologistsInternal medicine & family medicine cliniciansAPPs (NPs, PAs)Medical traineesPatients living with AFibAnyone using a smartwatch for heart rhythm monitoringAbout EP-Edge Journal Watch EP-Edge Journal Watch delivers high-level electrophysiology insights, clinical trial reviews, and real-world practice frameworks — with every episode designed to help clinicians make smarter, faster, evidence-based decisions. Subscribe for in-depth analyses of landmark EP trials, AFib management strategies, ablation literature, device therapy updates, and translational insights shaping the future of arrhythmia care.

In this special EP Edge Journal Watch episode, Dr. Niraj Sharma delivers a critical analysis of the landmark AQUATIC Trial, published in the New England Journal of Medicine (October 2025). This pivotal study explores optimal antithrombotic strategies in patients with atrial fibrillation (AF) and coronary artery disease (CAD) — balancing ischemic protection with bleeding risk. Dr. Sharma dissects trial design, outcomes, and clinical implications, comparing AQUATIC with AUGUSTUS, AFIRE, and AST-Efficient trials, and provides practical insights for real-world decision-making. Stay tuned for concise, evidence-driven interpretation — where every data point translates into better patient care. EP Edge Journal Watch Podcast — From Data to Decision in Cardiac Electrophysiology.

In this episode, Dr. Niraj Sharma breaks down six pivotal studies shaping today’s electrophysiology and cardiology practice—from lifestyle-driven AF control (ARREST-AF) and post-CABG atrial fibrillation management to the DOAC + aspirin conundrum in stable CAD, the return of digitoxin in HFrEF, insights from CABANA-Substudy, and the latest ICD registry data on shock rates. 

In this inaugural episode, Dr. Niraj Sharma breaks down three pivotal studies that could shift daily EP practice: How high-normal potassium targeting can reduce VT burden (POT-CAST trial).When GDMT withdrawal may be safe after recovery from tachycardia-induced cardiomyopathy.Why adverse pregnancy outcomes may predict long-term AF risk.Get the signal — not the noise — with expert analysis, clinical context, and practical takeaways for the EP lab.